 SÃO PAULO, Brazil and BOSTON, Aug. 24, 2021 PRNewswire -- Dasa, the largest integrated healthcare network in Brazil, has chosen to expand upon its partnership with SOPHiA GENETICS SA Nasdaq: SOPH to offer the first decentralized HRD Homologous recombination deficiency analytics solution in Latin America. HRD is a complex biomarker, important for PARP inhibitors, that helps identify whether cancer patients may respond better to specific treatments, and its use could ultimately lead to personalized therapies that benefit the individual patient. 